Antibody Response to COVID-19 mRNA Vaccine in Patients With Lung Cancer After Primary Immunization and Booster: Reactivity to the SARS-CoV-2 WT Virus and Omicron Variant.
Rajesh M ValanparambilJennifer Wilkinson CarlisleSusanne L LindermanAkil AktharRalph Linwood MillettLilin LaiAndres ChangAshley Alesia McCookJeffrey M SwitchenkoTahseen H NastiManpreet SainiAndreas WielandKelly E ManningMadison Leigh EllisKathryn M MooreStephanie L FosterKatharine FloydMeredith E Davis-GardnerVenkata-Viswanadh EdaraMit PatelConor E SteuerAjay K NookaFelicia GreenMargaret A JohnsFiona O'BreinUma ShanmugasundaramVeronika I ZarnitsynaHasan AhmedLindsay E NyhoffGrace MantusMichael GarettSrilatha EdupugantiMadhusmita BehraMorie A GertzJens WrammertMehul S SutharMadhav V DhodapkarSuresh R RamalingamRajesh M ValanparambilPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
A subset of patients with NSCLC responded poorly to the SARS-CoV-2 mRNA vaccination and had low neutralizing antibodies to the B.1.1.529 Omicron variant. Booster vaccination increased binding and neutralizing antibody titers to Omicron, but antibody titers declined after 3 months. These data highlight the concern for patients with cancer given the rapid spread of SARS-CoV-2 Omicron variant.